Alphatec Holdings, Inc. (NASDAQ:ATEC) is a company that focuses on providing innovative spinal surgery solutions. It operates in the Zacks Medical - Instruments industry, where it competes with other medical device companies. ATEC is committed to enhancing the predictability and effectiveness of spine surgeries through its technology and procedural solutions.
On August 5, 2025, Marshall Tyson Eliot, ATEC's General Counsel and Corporate Secretary, sold 9,924 shares of the company's common stock at $14.86 per share. This transaction, classified as an S-Sale, leaves Eliot with 446,499 shares of ATEC's common stock. This sale comes on the heels of ATEC's strong financial performance in the second quarter of 2025.
ATEC reported a 27% increase in revenue for Q2 2025, reaching $186 million, surpassing the analyst consensus estimate of $178.78 million. This growth reflects the company's expanding margins and increased surgeon adoption.
The company's non-GAAP earnings per share (EPS) were $0.02, a significant improvement from the anticipated non-GAAP loss of $0.04. This marks an earnings surprise of 133.33%, as highlighted by Zacks. ATEC's commitment to innovation and strategic direction was discussed in its Q2 2025 earnings conference call, providing insights into its financial performance.
Despite challenges, ATEC's financial metrics indicate a strong position. The current ratio of 2.88 suggests a robust ability to cover short-term liabilities. However, the enterprise value to operating cash flow ratio of 172.06 indicates limited cash flow relative to valuation. The debt-to-equity ratio of 24.68 reflects a relatively high level of debt compared to equity.
